The startup develops drugs that modulate the immune system by targeting the stimulator of interferon genes (STING) pathway, which plays a crucial role in the body's response to cancer and serious diseases. This approach enhances the immune response, potentially improving treatment outcomes for patients with cancer.

Anaveon is developing IL-2 complexes, specifically ANV419 and ANV600, which enhance effector T cell functions to improve immune responses in cancer treatment. The company addresses the need for safe and effective immunotherapies for patients with high unmet medical needs by utilizing protein engineering to optimize cytokine activity.

Beacon Therapeutics develops AAV gene therapy to treat blinding retinal diseases, including X-Linked Retinitis Pigmentosa, by introducing functional copies of mutated genes into patients' cells. This approach aims to restore vision and improve the quality of life for individuals affected by these conditions.

The startup develops therapeutics that protect heart function by preventing the loss of cardiomyocytes after myocardial infarction. This approach enables healthcare providers to minimize heart muscle damage during heart attacks, improving patient outcomes.

iOnctura develops precision oral small molecules targeting neglected and hard-to-treat cancers by modulating key signaling pathways, including allosteric modulation of PI3Kδ and inhibition of autotaxin. Their therapies aim to reduce the severe side effects associated with conventional treatments, thereby improving patient healthspan and overall survival.

Kesmalea Therapeutics is developing a pipeline of small molecule protein degraders using its SELFTAC® platform, which transforms large bifunctional degraders into orally bioavailable compounds that penetrate the central nervous system. This approach addresses the limitations of traditional protein degradation therapies by enhancing drug-like properties and expanding treatment options for chronic diseases, including oncology and CNS disorders.

Mos provides a financial platform for students that combines scholarship matching from a $160 billion database with personalized financial aid advisory services. This solution addresses the challenge of securing funding for education by simplifying the scholarship application process and enhancing access to financial resources.

Omass Therapeutics offers a proprietary platform that combines custom biochemistry, native mass spectrometry, and specialized chemistry to study membrane proteins and intracellular complexes in a near‑physiological, cell‑free environment. The technology quantifies binding affinities, kinetics, and functional outcomes, enabling pharmaceutical and biotech R&D teams to identify and optimize small‑molecule leads, including low‑affinity and allosteric binders, for orphan and immune‑mediated diseases.

Purespring Therapeutics develops AAV gene therapies specifically targeting podocytes to treat glomerular kidney diseases, including IgA nephropathy. The company addresses the lack of effective treatments for patients at risk of progressing to end-stage renal disease, offering a potential alternative to dialysis and kidney transplantation.

Develops engineered regulatory T cells (Tregs) to restore immune tolerance in patients with severe autoimmune, inflammatory, or transplant-related diseases. By rebalancing the immune system, these therapies aim to prevent tissue damage, chronic inflammation, and graft rejection, offering a potential long-term solution for conditions lacking effective treatments.

Resolution Therapeutics is developing macrophage cell therapies to treat inflammatory and fibrotic diseases, including liver cirrhosis, by utilizing engineered macrophages to promote organ repair and reduce the need for transplants. Their proprietary platform focuses on macrophage biology and manufacturing processes to deliver targeted therapeutic solutions for patients suffering from life-threatening organ damage.

This startup provides a platform that accelerates early-stage biotechnological research towards drug development. It offers infrastructure, sector expertise, and financial backing to academic founders, helping them advance scientific breakthroughs into clinical readiness.

Spur Therapeutics is developing targeted gene therapies that precisely modulate gene expression to halt the progression of chronic conditions such as Gaucher disease, Parkinson's, and certain cardiovascular diseases. By delivering a single dose of genetic medicine, the company aims to transform the treatment landscape for debilitating illnesses, improving patient outcomes and quality of life.

Yellowstone Bio develops off‑the‑shelf therapeutics that target frequently expressed, shared antigens on cancer cells, focusing on acute myeloid leukaemia and other high‑risk hematologic malignancies. Using a proprietary antigen discovery and validation platform, the company creates bispecific antibodies and T‑cell engagers designed for selective tumor killing while minimizing off‑target effects. Its pipeline is intended for licensing to pharma and biotech partners seeking ready‑to‑use, antigen‑targeted drug candidates.